OBJECTIVES: We compared the concentrations of the proinflammatory cytokine interleukin-2 (IL-2) with the anti-inflammatory cytokine interleukin-10 (IL-10) in serial serum samples from improved and expired acute ischemic stroke (AIS) patients to determine their prognostic usefulness. MATERIALS AND METHODS: Blood from AIS patients (n = 17) admitted within 24 h of the onset of symptoms were collected at admission and 24, 48, 72, and 144 h after admission. Pro- and anti-inflammatory cytokines were measured by enzyme-linked immunosorbant assay. RESULTS: IL-2 levels were elevated in serum samples from AIS patients collected at 0 (0.97, P < 0.01) and 24 h (1.011, P < 0.01). IL-2 concentrations gradually decreased at subsequent time-points (48, 72, and 144 h samples, 0.324, P < 0.05) in patients who improved (n = 13), but not in those who expired (n = 4). Similarly, a decrease in IL-10 levels was observed in serum samples from AIS patients who improved at 24 h (0.180, P < 0.05), followed by significant increases at 72 h (0.97, P < 0.01 vs. control) and 144 h (1.38, P < 0.01). CONCLUSION: The levels of IL-2 and IL-10 correlate well with outcome in AIS patients and may be useful in prognosis.
OBJECTIVES: We compared the concentrations of the proinflammatory cytokine interleukin-2 (IL-2) with the anti-inflammatory cytokine interleukin-10 (IL-10) in serial serum samples from improved and expired acute ischemic stroke (AIS) patients to determine their prognostic usefulness. MATERIALS AND METHODS: Blood from AISpatients (n = 17) admitted within 24 h of the onset of symptoms were collected at admission and 24, 48, 72, and 144 h after admission. Pro- and anti-inflammatory cytokines were measured by enzyme-linked immunosorbant assay. RESULTS:IL-2 levels were elevated in serum samples from AISpatients collected at 0 (0.97, P < 0.01) and 24 h (1.011, P < 0.01). IL-2 concentrations gradually decreased at subsequent time-points (48, 72, and 144 h samples, 0.324, P < 0.05) in patients who improved (n = 13), but not in those who expired (n = 4). Similarly, a decrease in IL-10 levels was observed in serum samples from AISpatients who improved at 24 h (0.180, P < 0.05), followed by significant increases at 72 h (0.97, P < 0.01 vs. control) and 144 h (1.38, P < 0.01). CONCLUSION: The levels of IL-2 and IL-10 correlate well with outcome in AISpatients and may be useful in prognosis.
Authors: T Sairanen; O Carpén; M L Karjalainen-Lindsberg; A Paetau; U Turpeinen; M Kaste; P J Lindsberg Journal: Stroke Date: 2001-08 Impact factor: 7.914
Authors: E van Exel; J Gussekloo; A J M de Craen; A Bootsma-van der Wiel; M Frölich; R G J Westendorp Journal: Stroke Date: 2002-04 Impact factor: 7.914
Authors: U Waje-Andreassen; J Kråkenes; E Ulvestad; L Thomassen; K-M Myhr; J Aarseth; C A Vedeler Journal: Acta Neurol Scand Date: 2005-06 Impact factor: 3.209
Authors: Catherine J Augello; Jessica M Noll; Timothy J Distel; Jolita D Wainright; Charles E Stout; Byron D Ford Journal: Brain Res Date: 2018-08-09 Impact factor: 3.252
Authors: Keri B Vartanian; Susan L Stevens; Brenda J Marsh; Rebecca Williams-Karnesky; Nikola S Lessov; Mary P Stenzel-Poore Journal: J Neuroinflammation Date: 2011-10-14 Impact factor: 8.322
Authors: Joshua M Garcia; Stephanie A Stillings; Jenna L Leclerc; Harrison Phillips; Nancy J Edwards; Steven A Robicsek; Brian L Hoh; Spiros Blackburn; Sylvain Doré Journal: Front Neurol Date: 2017-06-12 Impact factor: 4.003
Authors: Amit R Nayak; Rajpal S Kashyap; Dinesh Kabra; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala Journal: Ann Indian Acad Neurol Date: 2012-07 Impact factor: 1.383